Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 3/20 | 0.43 |
| ▸ | MAP2K1 | Q02750 | 13/20 | 0.38 |
| ▸ | MAP2K2 | P36507 | 7/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5990169 | 0.91 | MEN1 (0.43) | MEN1KMT2ATDP1IDO1MAP2K1 | |
| SCHEMBL5763796 | 0.90 | IDO1 (0.52) | MEN1KMT2ATDP1IDO1MAP2K1 | |
| SCHEMBL5988682 | 0.88 | MEN1 (0.45) | MEN1KMT2ATDP1IDO1MAP2K1 | |
| SCHEMBL1038046 | 0.88 | MAPT (0.42) | MEN1KMT2AMAP2K1MAP2K2GFER | |
| SCHEMBL1078430 | 0.86 | CYP2C9 (0.45) | MEN1KMT2A | |
| SCHEMBL27583344 | 0.84 | MEN1 (0.43) | MEN1KMT2ATDP1IDO1MAP2K1 | |
| SCHEMBL27583342 | 0.84 | MEN1 (0.43) | MEN1KMT2ATDP1IDO1MAP2K1 | |
| SCHEMBL5991762 | 0.84 | IDO1 (0.45) | MEN1KMT2ATDP1IDO1MAP2K1 | |
| SCHEMBL6137927 | 0.83 | IDO1 (0.40) | MEN1KMT2ATDP1IDO1MAP2K1 | |
| SCHEMBL5988793 | 0.81 | MEN1 (0.71) | MEN1KMT2ATDP1MAP2K1MAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663210-A4 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC (US) | 2009-04-22 | — | — | EP | disclosed |
| EP-1663210-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | Array Biopharma, Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20060106225-A1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA INC. | 2006-05-18 | — | — | US | disclosed |
| EP-1482944-A4 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC (US) | 2006-04-19 | — | — | EP | disclosed |
| US-7030119-B1 | Method for treating chronic pain using MEK inhibitors | WARNER-LAMBERT COMPANY (US) | 2006-04-18 | — | — | US | disclosed |
| EP-1482932-A4 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC (US) | 2006-04-05 | — | — | EP | disclosed |
| EP-1144385-B1 | BENZOHETEROCYCLES AND THEIR USE AS MEK INHIBITORS | WARNER LAMBERT CO (US) | 2005-08-17 | — | — | EP | disclosed |
| CN-1652792-A | N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA INC (US) | 2005-08-10 | — | — | CN | disclosed |
| WO-2005023251-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2005-03-17 | — | — | WO | disclosed |
| EP-1482932-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | Array Biopharma, Inc. (US) | 2004-12-08 | — | — | EP | disclosed |
| EP-1482944-A2 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | Array Biopharma, Inc. (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20030216460-A1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA, INC. | 2003-11-20 | — | — | US | disclosed |
| WO-2003077855-A2 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA, INC (US) | 2003-09-25 | — | — | WO | disclosed |
| WO-2003077914-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA, INC (US) | 2003-09-25 | — | — | WO | disclosed |
| US-6469004-B1 | Benzoheterocycles and their uses as MEK inhibitors | WARNER-LAMBERT COMPANY | 2002-10-22 | — | — | US | disclosed |
| EP-1202731-A2 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-05-08 | — | — | EP | disclosed |
| EP-1144385-A1 | BENZOHETEROCYCLES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2001005390-A2 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-01-25 | — | — | WO | disclosed |
| WO-2000042022-A1 | BENZOHETEROCYCLES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106225-A1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | CCNI, BRAF, CCNT1 | MEN1 1267/4885KMT2A 1335/4885TDP1 860/4885 |
| US-20030216460-A1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | CCNI, BRAF, CCNT1 | MEN1 1679/4885KMT2A 1029/4885TDP1 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.